Premium
Interleukin‐15 blocks apoptosis and induces proliferation of the human myeloma cell line OH‐2 and freshly isolated myeloma cells
Author(s) -
HjorthHansen Henrik,
Waage Anders,
Börset Magne
Publication year - 1999
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1999.01510.x
Subject(s) - cytokine , cell culture , cell growth , lymphotoxin , cancer research , tumor necrosis factor alpha , apoptosis , multiple myeloma , interleukin 6 , interleukin , growth factor , biology , microbiology and biotechnology , immunology , medicine , receptor , biochemistry , genetics
The growth factor‐dependent myeloma cell line OH‐2, which has previously been shown to be responsive to interleukin (IL)‐6, tumour necrosis factor (TNF)‐α and lymphotoxin, was examined for response to other growth factors. Enhanced proliferation was found in the presence of IL‐10, IL‐15, IL‐2 and insulin growth factor (IGF)‐1. Proliferation was strongest in response to IL‐6, intermediate and roughly equipotent in response to IL‐15, IL‐10 and TNF‐α, and modest in response to IL‐2 and IGF‐1. IL‐15 was synergistic with TNF‐α, whereas combinations of IL‐15 and the other cytokines were merely additive. IL‐15‐induced proliferation could not be blocked by neutralizing antibody against gp 130, the common transducer chain of IL‐6 and related cytokines. IL‐15 and IL‐6 prevented apoptosis equally well, both better than TNF‐α, IL‐10, and IGF‐1. In four out of six samples of purified primary cells, IL‐15 and IL‐6 induced proliferation. Furthermore, IL‐15 mRNA was detected by RT‐PCR in most myeloma cell lines and freshly isolated purified patient samples. IL‐15 protein was detectable only in one out of about 20 tested cell supernatants from patients and myeloma cell lines. The OH‐2 cell line is multi‐responsive to cytokines and is a good system for the study of integration of cytokine signal transduction and growth control in myeloma. IL‐15 represents a novel modality of growth regulation in myeloma.